Chiba

Futó vizsgálatok

• Toboroz

  Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  NCT07816666· 3. fázis· Forrás

• Toboroz

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· 3. fázis· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Toboroz

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· 3. fázis· Forrás

• Toboroz

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· 2. fázis· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· Forrás

• Toboroz

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· 2. fázis· Forrás

• Fut, nem toboroz

  A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

  NCT06564844· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· Forrás

• Toboroz

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· 3. fázis· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· Forrás

• Fut, nem toboroz

  Fasenra Pediatric Japan Post-Marketing Study(PMS)

  NCT06427876· Forrás

• Fut, nem toboroz

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· 3. fázis· Forrás

• Toboroz

  An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  NCT05835310· 3. fázis· Forrás

• Toboroz

  AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  NCT06137118· 1/2. fázis· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· Forrás

• Toboroz

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· 3. fázis· Forrás

• Fut, nem toboroz

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· 3. fázis· Forrás

• Fut, nem toboroz

  TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

  NCT05729711· Forrás

• Fut, nem toboroz

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· 3. fázis· Forrás

• Fut, nem toboroz

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT05348577· 3. fázis· Forrás

• Fut, nem toboroz

  A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

  NCT05120349· 3. fázis· Forrás

• Fut, nem toboroz

  A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

  NCT05211895· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

  NCT05138133· 3. fázis· Forrás

• Fut, nem toboroz

  SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

  NCT05141201· Forrás

• Fut, nem toboroz

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  NCT04862663· 3. fázis· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  NCT04711252· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

  NCT04351555· 3. fázis· Forrás

• Fut, nem toboroz

  A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

  NCT04529772· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

  NCT04305496· 3. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

  NCT04157348· 3. fázis· Forrás

• Fut, nem toboroz

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  NCT03298451· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Máj- és epeúti rák3 toboroz
• Follikuláris limfóma2 toboroz
• Prosztatarák2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Áttétes emlőrák1 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyermekkori daganatok1 toboroz
• Hodgkin-limfóma1 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)1 toboroz
• Krónikus vesebetegség1 toboroz
• Lupus (SLE)1 toboroz
• Petefészekrák1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients

  NCT07101874· Forrás

• Lezárult

  Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

  NCT05665374· Forrás

• Lezárult

  Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

  NCT05835778· Forrás

• Lezárult

  Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

  NCT05826366· Forrás

• Lezárult

  LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

  NCT05677308· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Forrás

• Lezárult

  A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05364931· 2. fázis· Forrás

• Lezárult

  Forxiga CKD Japan Post-Marketing Surveillance (PMS)

  NCT05306210· Forrás

• Leállították

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· 3. fázis· Forrás

• Lezárult

  Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

  NCT04872621· Forrás

• Lezárult

  LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

  NCT04889404· Forrás

• Lezárult

  Forxiga HF General Drug Use-Results Study

  NCT04865406· Forrás

• Leállították

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· 3. fázis· Forrás

• Lezárult

  An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

  NCT04201262· 3. fázis· Forrás

• Lezárult

  Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

  NCT03995875· Forrás

• Lezárult

  FASENRA SCEI for Long-term Use

  NCT03588546· Forrás

• Lezárult

  Brilinta Clinical Experience Investigation

  NCT03212287· Forrás

• Lezárult

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· 1/2. fázis· Forrás